Haemonetics Corporation  

(Public, NYSE:HAE)   Watch this stock  
Find more results for HAE
45.66
+0.55 (1.22%)
Oct 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 45.47 - 46.15
52 week 32.76 - 46.85
Open 45.57
Vol / Avg. 349,615.00/322,510.00
Mkt cap 2.40B
P/E 596.78
Div/yield     -
EPS 0.08
Shares 52.61M
Beta 0.87
Inst. own 107%
Nov 7, 2017
Q2 2018 Haemonetics Corp Earnings Call - 8:00AM EST - Add to calendar
Nov 7, 2017
Q2 2018 Haemonetics Corp Earnings Release - 6:00AM EST - Add to calendar
Sep 11, 2017
Haemonetics Corp at Morgan Stanley Healthcare Conference - Webcast
Aug 7, 2017
Q1 2018 Haemonetics Corp Earnings Call - Webcast
Aug 7, 2017
Q1 2018 Haemonetics Corp Earnings Release
Jul 27, 2017
Haemonetics Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q3 (Jul '17) 2017
Net profit margin 9.55% -2.96%
Operating margin 11.67% -2.19%
EBITD margin - 16.13%
Return on average assets 6.49% -2.05%
Return on average equity 10.68% -3.60%
Employees 3,107 -
CDP Score - -

Address

400 WOOD RD
BRAINTREE, MA 02184-2412
United States - Map
+1-781-8487100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

Officers and directors

Christopher Simon President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
William P. Burke Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
David J. Wilson President - Plasma Business Unit
Bio & Compensation  - Reuters
Michelle Basil Executive Vice President, General Counsel
Age: 45
Bio & Compensation  - Reuters
Neil Ryding Executive Vice President, Global Operations
Age: 56
Bio & Compensation  - Reuters
Richard J. Meelia Non-Executive Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Robert E. Abernathy Director
Age: 62
Bio & Compensation  - Reuters
Catherine M. Burzik Independent Director
Age: 66
Bio & Compensation  - Reuters
Charles J. Dockendorff Independent Director
Age: 62
Bio & Compensation  - Reuters
Susan Bartlett Foote Independent Director
Age: 70
Bio & Compensation  - Reuters